Urogen Pharma (URGN) vs Vericel Corporation (VCEL)
Urogen Pharma and Vericel Corporation are both Biotechnology companies. Urogen Pharma and Vericel Corporation are of similar size ($2.0B and $2.0B). Urogen Pharma has negative trailing earnings, so its P/E is not meaningful; Vericel Corporation trades at 82.6×. Urogen Pharma grew revenue faster over the last twelve months: 100.3% against 23.0%. Vericel Corporation has the higher net margin (7.91% vs −51.7%) and the higher return on invested capital (5.49% vs 0.00%). Across the 18 metrics below, Vericel Corporation leads on 13 and Urogen Pharma on 5.
Valuation
Profitability
| Metric | URGN | VCEL | Biotechnology median |
|---|---|---|---|
| Gross margin | 90.85% | 74.56% | 65.16% |
| Operating margin | (35.32%) | 5.95% | 0.00% |
| Net margin | (51.73%) | 7.91% | 0.00% |
| Free cash flow margin | (84.32%) | 20.13% | 0.00% |
| Return on equity | 86.49% | 7.16% | (57.72%) |
| Return on assets | (42.33%) | 5.16% | (49.22%) |
| Return on invested capital | 0.00% | 5.49% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack